The European Commission (EC) has granted approval for Horizon Therapeutics’ Uplizna (inebilizumab) as monotherapy to treat neuromyelitis optica spectrum disorder (NMOSD) in adults. The treatment is intended for NMOSD patients who are anti-aquaporin-4 immunoglobulin G […]
Genesis Therapeutics and Eli Lilly and Company have signed a strategic partnership for discovering new drugs for up to five targets across various therapeutic areas. The alliance will leverage the artificial intelligence (AI) drug discovery […]
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference […]
The European Commission (EC) has updated the marketing authorization for Sanofi and Regeneron’s Dupixent (adupilumab) to include as an add-on maintenance treatment for severe asthma with type 2 inflammation in children of the age six […]
Jazz Pharmaceuticals has signed a licencing agreement to acquire exclusive international rights to develop and market Werewolf Therapeutics’ investigational cancer therapy, WTX-613. A differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE molecule, WTX-613 is presently in the […]